Roche Diagnostics Launches Two Cancer Drug Testing Agents In Japan
This article was originally published in PharmAsia News
Roche Diagnostics plans to launch the biomarker KRASfor Merck Serono's colon cancer drug Erbitux (cetuximab) in March. KRAS will be used to test genotypes when administering colon cancer drugs to decide the relationship between genotypes and drug efficacy. The company also plans to launches EGFRtesting for lung cancer drugs this summer, which will be used to assess efficacy of AstraZeneca's Iressa (gefitinib) and Chugai's Tarceva (erlotinib). (Click here for more - Japanese language
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.